此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

2026年8月7日 更新者:Rigel Pharmaceuticals

A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors

An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors

研究概览

研究类型

介入性

注册 (估计的)

12

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Must be willing and able to participate and comply with all study requirements and to provide signed and dated written informed consent
  • Adult male or female ≥ 18 years of age at the time of signing the informed consent form.
  • Must have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m² and a minimum body weight of 50 kg at screening.
  • Must have an Eastern Cooperative Oncology Group performance status ≤ 2.
  • Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)
  • Must have a confirmed diagnosis of advanced or metastatic solid tumor that has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.
  • Must have adequate organ function, defined by the following:

    1. Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L.
    2. Platelet count ≥ 75 × 10⁹/L.
    3. Hemoglobin ≥ 9 g/dL.
    4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with known liver metastases.
    5. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in patients with Gilbert syndrome).
    6. Creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation.
    7. Serum phosphorus ≤ 5.5 mg/dL.
    8. International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) within normal laboratory limits.
  • Must be at least 4 weeks from major surgery, radiotherapy, chemotherapy, immunotherapy, kinase/targeted therapy, or gene therapy prior to the first dose of study treatment and recovered from treatment-related toxicities to ≤ Grade 1 (excluding alopecia). Must be ≥ 6 weeks since last treatment if they received a long-acting agent such as a nitrosourea, mitomycin, or monoclonal antibodies. In general, a treatment interval of two half-lives should be considered and discussed with the Sponsor. (Concurrent cancer therapy of any type is not permitted).
  • Female patients may participate if they are not of childbearing potential (e.g., surgically sterile or postmenopausal).
  • Male patients with female partners of childbearing potential must agree to use highly effective contraception during study treatment and for 90 days after the last dose of study treatment.
  • Male patients must refrain from sperm donation during study treatment and for 90 days after the last dose of study treatment.

Exclusion Criteria:

  • Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at screening that, in the investigator's judgment, are likely to interfere with the objectives of the trial or the safety of the patient.
  • Surgery (e.g., gastric bypass) or medical condition that may significantly affect absorption of study medications, as judged by the investigator.
  • History of pneumonitis within the last 12 months.
  • History of active or latent tuberculosis (TB), regardless of treatment history, or a positive screening test for latent Mycobacterium tuberculosis infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat testing or by a purified protein derivative (PPD) skin test.
  • Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the investigator, could impact patient safety (e.g., COVID-19 or influenza).
  • Clinically significant, uncontrolled cardiovascular disease, including:

    1. New York Heart Association (NYHA) Class III or IV congestive heart failure.
    2. Myocardial infarction or unstable angina within the previous 6 months, clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (e.g., second- or third-degree heart block).
    3. Uncontrolled hypertension (i.e., mean systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg on 3 repeated measurements) or clinically significant hypotension (i.e., systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg) or severe episodes of orthostatic hypotension.
    4. History of prolonged QT syndrome or torsades de pointes, or familial history of long QT syndrome.
    5. QTcF ≥470 ms on at least 2 ECGs performed >30 minutes apart.
  • Central nervous system (CNS) metastases or primary CNS tumor.
  • Use of systemic corticosteroids within 4 weeks prior to first dose of study treatment.
  • More than 30 Gy of radiotherapy to the lung within 6 months prior to check-in.
  • History of multiple and/or severe allergies to drugs or foods, or history of severe anaphylactic reaction.
  • Use of prohibited medications or procedures
  • Medical conditions, treatments, or underlying diseases that constitute contraindications to the use of study substrates or probe drugs
  • Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.
  • Participation in another investigational drug trial within 30 days prior to study drug administration (or within 5 half-lives of the investigational drug, whichever is longer) or exposure to more than 3 investigational agents within 12 months prior to study drug administration.
  • Positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening (a negative PCR test overrides a positive serology).
  • Positive human immunodeficiency virus (HIV) test at screening.
  • Positive urine drug screen (unless attributable to concomitant medication) or positive alcohol breath test at screening and/or Day -1.
  • Patients who are legally incapacitated, have limited legal capacity, or are otherwise considered vulnerable.
  • Female patients who are pregnant or breastfeeding.
  • Patients who plan to become pregnant or father a child (including ova or sperm donation) during the study or within 3 months after the last dose of study drug.
  • Known allergy or history of hypersensitivity to study drug(s) or their excipients.
  • Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
  • Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
  • History of or active clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatologic, hematologic, or other disorder that, in the investigator's judgment, could interfere with study participation or the absorption, metabolism, or excretion of study treatment.
  • History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Pralsetinib with CYP450 Probe Substrates and Hormonal Contraceptive
Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33
Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)
大体时间:Up to 48 hours post-dose or as appropriate for each probe substrate
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9, probe substrates, and hormonal contraceptive by measuring AUC0-inf for each probe substrate and its relevant metabolites.
Up to 48 hours post-dose or as appropriate for each probe substrate
Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)
大体时间:Up to 48 hours after each probe drug administration
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9 probe substrates, and hormonal contraceptive by measuring AUClast for each probe substrate and its relevant metabolites.
Up to 48 hours after each probe drug administration
Maximum Peak Plasma Concentration (Cmax)
大体时间:Up to 48 hours after each probe drug administration
To evaluate how pralsetinib affects the peak levels of probe substrates, and hormonal contraceptive, in the blood after they are taken alone and again after treatment with pralsetinib
Up to 48 hours after each probe drug administration

次要结果测量

结果测量
措施说明
大体时间
Time to Maximum Plasma Concentration (tmax)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the time required to reach peak plasma concentration for each probe drug.
Up to 48 hours after each probe drug administration
Terminal Half-Life (t½)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization To evaluate the effect of pralsetinib on the terminal half-life of each probe drug
Up to 48 hours after each probe drug administration
Percent of Area Under the plasma concentration-time curve obtained at extrapolation (%AUCex)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to determine the proportion of the AUC that is extrapolated, providing insight into pralsetinib's effect on drug elimination
Up to 48 hours after each probe drug administration
Mean residence time (MRT)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the average time each probe drug remains in the body
Up to 48 hours after each probe drug administration
Terminal Elimination Rate Constant (λz)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the terminal elimination rate constant of each probe drug
Up to 48 hours after each probe drug administration
Apparent Total Body Clearance (CL/F)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to evaluate the effect of pralsetinib on the apparent total body clearance of each probe drug
Up to 48 hours after each probe drug administration
Apparent Volume of Distribution (Vz/F)
大体时间:Up to 48 hours after each probe drug administration
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib influences the apparent volume of distribution of each probe drug
Up to 48 hours after each probe drug administration
Safety and Tolerability
大体时间:From the start of treatment through approximately 30 days after the last dose of study treatment
Incidence, frequency, relatedness, and severity of treatment-emergent adverse events (TEAEs) associated with co-administration of pralsetinib and probe substrates
From the start of treatment through approximately 30 days after the last dose of study treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月4日

初级完成 (估计的)

2027年7月30日

研究完成 (估计的)

2027年8月30日

研究注册日期

首次提交

2026年7月9日

首先提交符合 QC 标准的

2026年7月9日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年8月10日

上次提交的符合 QC 标准的更新

2026年8月7日

最后验证

2026年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅